Papers from every journal, all in one place。 カスタムフィードを作成できます。
IS
Dr. Inderjit Singh
Director of the Pulmonary Vascular Disease Program · Yale School of Medicine
“
As a clinician, preventing hemodynamic deterioration in the intermediate-high-risk group is meaningful. If these findings are replicated and reflected in future guideline updates, there may be a shift from reactive management towards a more proactive reperfusion strategy in carefully selected intermediate-risk pulmonary embolism patients.
Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism
New England Journal of Medicine
ACC Journal Scan
“
The risk of heart attack and stroke is a concern for older people and knowing there is an effective measure for lowering that risk will be a huge reassurance to older people and their families. We hope to see updated guidelines to help clinicians make use of these new findings.
Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults
New England Journal of Medicine
Boyoung Joung
“
The key impact on clinical practice is that the level of evidence about this population was actually very low, and this is the first [randomized controlled trial] to support that DOAC therapy can give benefit to this patient population.
Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk
New England Journal of Medicine
ACC Journal Scan
“
For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease.
Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
New England Journal of Medicine
ACC Journal Scan
“
“Despite major advances in pharmacologic and device-based therapies, pulmonary hypertension remains one of the strongest predictors of hospitalization, right ventricular failure, and death in patients with left heart disease and heart failure.”
Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension